Finch Therapeutics Group, Inc. (NASDAQ:FNCH – Get Free Report)’s share price was up 1.2% on Wednesday . The company traded as high as $12.00 and last traded at $12.00. Approximately 2,105 shares were traded during trading, a decline of 92% from the average daily volume of 26,622 shares. The stock had previously closed at $11.86.
Finch Therapeutics Group Stock Performance
The firm has a market cap of $19.32 million, a P/E ratio of -1.36 and a beta of 1.34. The business’s 50-day simple moving average is $11.68 and its 200 day simple moving average is $7.15.
About Finch Therapeutics Group
Finch Therapeutics Group, Inc, a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates.
Recommended Stories
- Five stocks we like better than Finch Therapeutics Group
- What Do S&P 500 Stocks Tell Investors About the Market?
- Microsoft Stock Gets a $550 Price Target: Time to Get Excited
- CD Calculator: Certificate of Deposit Calculator
- Trump Tariffs in Focus: 2 Chinese Stocks to Own and 2 to Avoid
- Do ETFs Pay Dividends? What You Need to Know
- 2 Generic Drug Stocks Ready to Surge in 2025
Receive News & Ratings for Finch Therapeutics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Finch Therapeutics Group and related companies with MarketBeat.com's FREE daily email newsletter.
